Zobrazeno 1 - 10
of 461
pro vyhledávání: '"John Shaughnessy"'
Autor:
Raghad Alqazaqi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John Shaughnessy, Fenghuang Zhan, Guido Tricot, Frits van Rhee, Samer Al Hadidi
Publikováno v:
JAMA network open. 5(8)
ImportanceThe use of chimeric antigen receptor–T cell (CAR-T) therapy and bispecific antibodies in multiple myeloma is expanding, with encouraging early results. It is unknown if the current geographic distribution of CAR-T therapy and bispecific a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2847b30390a120b8971eba7f7f36e174
https://pubmed.ncbi.nlm.nih.gov/36018590
https://pubmed.ncbi.nlm.nih.gov/36018590
Autor:
Samer Al Hadidi, Deepa Dongarwar, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John Shaughnessy, Frits van Rhee Van Rhee
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S102-S103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5672c08cc067f697e3ed5c2980d12159
https://doi.org/10.1016/s2152-2650(22)00452-9
https://doi.org/10.1016/s2152-2650(22)00452-9
Publikováno v:
Hematology. 2004:237-256
High-dose therapy with stem cell transplantation (SCT) and novel targeted therapies (thalidomide, its more potent analogues, and bortezomib) represent two approaches for overcoming resistance of multiple myeloma (MM) cells to conventional therapies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eecbc6806395fc76a7055f6fbdbeaca5
https://doi.org/10.1182/asheducation-2004.1.237
https://doi.org/10.1182/asheducation-2004.1.237
Publikováno v:
Resistance to Targeted Anti-Cancer Therapeutics ISBN: 9783319067513
Treatment regimens for MM patients have undergone considerable modifications from the 1960s in an attempt to achieve that elusive “complete cure.” Proteasome inhibitors such as bortezomib (Bz) have recently become effective chemotherapeutic agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::224e9092f63bac93a0720ea6285215a8
https://doi.org/10.1007/978-3-319-06752-0_5
https://doi.org/10.1007/978-3-319-06752-0_5
Autor:
James Peter, Stewart, Alexander, Thompson, Madhumita, Santra, Bart, Barlogie, Terence R J, Lappin, John, Shaughnessy
Publikováno v:
British journal of haematology. 126(1)
The t(4;14)(p16;q32) translocation seen in c. 18% of newly diagnosed multiple myeloma (MM) cases, results in FGFR3 activation and creation of an IGH/MMSET fusion transcript. We have recently shown that FGFR3 is activated in only 75% of t(4;14)(+) cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d534ef5201337cc4ec1c0247541fb9fc
https://pubmed.ncbi.nlm.nih.gov/15198734
https://pubmed.ncbi.nlm.nih.gov/15198734
Autor:
Thomas, Kelly, Hua-Quan, Miao, Yang, Yang, Elizabeth, Navarro, Paul, Kussie, Yan, Huang, Veronica, MacLeod, Jonathan, Casciano, Lija, Joseph, Fenghuang, Zhan, Maurizio, Zangari, Bart, Barlogie, John, Shaughnessy, Ralph D, Sanderson
Publikováno v:
Cancer research. 63(24)
Heparanase is an enzyme that cleaves heparan sulfate chains of proteoglycans, and its expression has been associated with increased growth, metastasis, and angiogenesis of some tumors. Because myeloma tumor cells express high levels of the syndecan-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::81ca6e5abb6605fd9b669aa4109767bc
https://pubmed.ncbi.nlm.nih.gov/14695190
https://pubmed.ncbi.nlm.nih.gov/14695190
Autor:
Sophie, Barillé-Nion, Bart, Barlogie, Régis, Bataille, P Leif, Bergsagel, Joshua, Epstein, Robert G, Fenton, Joth, Jacobson, W Michael, Kuehl, John, Shaughnessy, Guido, Tricot
Publikováno v:
Hematology. American Society of Hematology. Education Program.
Even during this past year, further advances have been made in understanding the molecular genetics of the disease, the mechanisms involved in the generation of myeloma-associated bone disease and elucidation of critical signaling pathways as therape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c59b32649a22b54b24a40787a0d2d9dc
https://pubmed.ncbi.nlm.nih.gov/14633785
https://pubmed.ncbi.nlm.nih.gov/14633785
Autor:
Joth, Jacobson, Bart, Barlogie, John, Shaughnessy, Johannes, Drach, Guido, Tricot, Athanasios, Fassas, Maurizio, Zangari, Dori, Giroux, John, Crowley, Aubrey, Hough, Jeff, Sawyer
Publikováno v:
British journal of haematology. 122(3)
Cytogenetic abnormalities (CA), especially of chromosome 13, have been used to identify a subgroup of previously untreated multiple myeloma (MM) patients with very poor prognosis despite high-dose therapy (HDT). We examined the prognostic implication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::36cddf5fb7b8ede0c60b7ddb29c31022
https://pubmed.ncbi.nlm.nih.gov/12877670
https://pubmed.ncbi.nlm.nih.gov/12877670
Autor:
Jeroen E J, Guikema, Sjoerd, Hovenga, Edo, Vellenga, Jelle J, Conradie, Wayel H, Abdulahad, Roelof, Bekkema, Jan W, Smit, Fenghuang, Zhan, John, Shaughnessy, Nicolaas A, Bos
Publikováno v:
British journal of haematology. 121(1)
Expression of CD27 on malignant plasma cells (PC) (CD138+CD38++) was analysed in a cross-sectional study of bone marrow (BM) samples from multiple myeloma (MM) patients (n = 28), monoclonal gammopathy of undetermined significance (MGUS) patients (n =
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cdd07a9282a8391e98807670fc25651d
https://pubmed.ncbi.nlm.nih.gov/12670329
https://pubmed.ncbi.nlm.nih.gov/12670329